Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy
- PMID: 19362942
- DOI: 10.3816/CLC.2009.s.003
Combined inhibition of vascular endothelial growth factor and epidermal growth factor signaling in non-small-cell lung cancer therapy
Abstract
Elucidation of molecular pathways that promote malignancies has led to the identification of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) as key components involved in regulation of tumor proliferation and angiogenesis, respectively. Biologic agents that target these individual pathways have proven effective in treating patients with advanced non-small-cell lung cancer (NSCLC), adding to previously available therapies and often with fewer side effects. However, inhibition of a single molecular pathway does not account for alternate pathways or biologic adaptations that eventually lead to resistance. Therefore, combining EGFR and VEGF inhibition is currently under investigation as a means to overcome resistance and promote synergy. Erlotinib, an anti-EGFR agent, and bevacizumab, an anti-VEGF agent, are both approved in NSCLC, demonstrating single-agent activity. The phase II trials evaluating the combination of erlotinib and bevacizumab have shown efficacy as first-line therapy or in patients with previously treated NSCLC either alone or with chemotherapy. Dual inhibition of EGFR and VEGF pathways has also been accomplished by the novel agents vandetanib and XL647, which are able to target both pathways. Vandetanib has also demonstrated activity in patients with advanced NSCLC either alone or with chemotherapy in phase I/II studies. Another novel agent, XL647, has demonstrated promising single-agent activity in patients who have been resistant to previous anti-EGFR therapy. Further evaluation of combined EGFR and VEGF inhibition is under investigation.
Similar articles
-
Targeted therapy in advanced non-small-cell lung cancer.Semin Respir Crit Care Med. 2008 Jun;29(3):291-301. doi: 10.1055/s-2008-1076749. Semin Respir Crit Care Med. 2008. PMID: 18506667 Review.
-
Combined vascular endothelial growth factor receptor and epidermal growth factor receptor (EGFR) blockade inhibits tumor growth in xenograft models of EGFR inhibitor resistance.Clin Cancer Res. 2009 May 15;15(10):3484-94. doi: 10.1158/1078-0432.CCR-08-2904. Epub 2009 May 15. Clin Cancer Res. 2009. PMID: 19447865 Free PMC article.
-
Role of anti-angiogenesis agents in treating NSCLC: focus on bevacizumab and VEGFR tyrosine kinase inhibitors.Curr Treat Options Oncol. 2007 Feb;8(1):15-27. doi: 10.1007/s11864-007-0022-4. Curr Treat Options Oncol. 2007. PMID: 17634832 Review.
-
Investigational agents in the management of non-small cell lung cancer.Curr Oncol Rep. 2009 Jul;11(4):275-84. doi: 10.1007/s11912-009-0039-x. Curr Oncol Rep. 2009. PMID: 19508832 Review.
-
Addition of bevacizumab enhances antitumor activity of erlotinib against non-small cell lung cancer xenografts depending on VEGF expression.Cancer Chemother Pharmacol. 2014 Dec;74(6):1297-305. doi: 10.1007/s00280-014-2610-x. Epub 2014 Oct 26. Cancer Chemother Pharmacol. 2014. PMID: 25344762 Free PMC article.
Cited by
-
New antiproliferative 3-substituted oxindoles inhibiting EGFR/VEGFR-2 and tubulin polymerization.Mol Divers. 2024 Apr;28(2):563-580. doi: 10.1007/s11030-023-10603-z. Epub 2023 Feb 15. Mol Divers. 2024. PMID: 36790582 Free PMC article.
-
A Pilot Study: Favorable Effects of Clostridium butyricum on Intestinal Microbiota for Adjuvant Therapy of Lung Cancer.Cancers (Basel). 2022 Jul 23;14(15):3599. doi: 10.3390/cancers14153599. Cancers (Basel). 2022. PMID: 35892858 Free PMC article.
-
Association between survivin genetic polymorphisms and epidermal growth factor receptor mutation in non-small-cell lung cancer.Int J Med Sci. 2016 Nov 23;13(12):929-935. doi: 10.7150/ijms.16875. eCollection 2016. Int J Med Sci. 2016. PMID: 27994498 Free PMC article.
-
Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts.Target Oncol. 2016 Aug;11(4):507-14. doi: 10.1007/s11523-015-0415-4. Target Oncol. 2016. PMID: 26817645
-
Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches.Cancer Metastasis Rev. 2015 Mar;34(1):19-40. doi: 10.1007/s10555-014-9538-9. Cancer Metastasis Rev. 2015. PMID: 25544368 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous